Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Merck's Keytruda to gain 3rd approval for endometrial cancer

<< Previous

Bullboard Posts

Next >>

Comment by jimsenioron Feb 03, 2023 12:13pm

188 Views

Post# 35265117

RE:RE:Merck's Keytruda to gain 3rd approval for endometrial cancer

ONC/ONCY has orphan drug staus for ovarian, fallopian tube and peritoneal cancers from the EMA. I believe also from the FDA but I have not checked. Endometrial cancer is likely included in the above, but I have not confirmed.

See News Release March 25, 2015.

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023